NLEX
Purchase-Price Allocation
Goodwill
$3.5M
HERITAGE GLOBAL INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$0
Book Value Per Share
$2
Free Cash Flow Per Share
$-0
Cash Per Share
$1
Revenue Per Share
$1
OCF Per Share
$0
Return on Equity
5.4%
Return on Assets
4.2%
Return on Invested Capital
5.3%
Debt to Equity
—
Current Ratio
2.16
Quick Ratio
1.78
Asset Turnover
0.60
Days Sales Outstanding
13.30
Days Inventory On Hand
58.51
SBC / Revenue
1.8%
Capex / Revenue
16.6%
Working Capital
$18M
Net Current Asset Value
$12M
Invested Capital
$67M
OCF / Net Income
1.71
FCF / Net Income
-0.65
Accruals Ratio (Sloan)
-2.9%
Net Debt
$-21M
Net Debt / EBITDA
-3.32
Interest Coverage
—
Cash Coverage
—
Capex Coverage
0.72
Tangible Common Equity
$56M
TCE / Total Assets
63.8%
Goodwill / Total Assets
8.4%
NOPAT
$4M
Cash ROIC
-3.5%
WC / Revenue
35.4%
Capex / D&A
17.94
Reinvestment Rate
140.0%
Total Payout Ratio
73.2%
Asset Growth vs Revenue Growth
-3.6%
Revenue 5Y CAGR
14.3%
EPS 5Y CAGR
-18.0%
FCF 5Y CAGR
62.2%
EBITDA 5Y CAGR
-0.8%
Book Value 5Y CAGR
17.5%
Stock Price (FY-end)
$1
Market Cap
$44M
P/E Ratio
12.25
P/S Ratio
0.86
P/B Ratio
0.66
P/TB Ratio
0.78
P/OCF Ratio
7.16
P/FCF Ratio
9.03
Enterprise Value
$23M
EV / EBITDA
3.79
EV / Sales
0.46
EV / FCF
6.17
FCF Yield
-5.3%
Shareholder Yield
3.9%
Buyback Yield
6.0%
Capex Yield
19.3%
Operating Leverage
-2.99
Graham Number
$2
Shares Variation (YoY)
-4.6%
Beta (5Y)
0.43
Cost of Equity
6.6%
Cost of Debt (after tax)
—
WACC
—
ROIC - WACC Spread
—
52W High
$2
52W Low
$1
Trailing Return 1Y
-27.9%
Trailing Return 5Y
-60.5%
F-Score (Piotroski)
5.00
Z-Score (Altman)
-1.29
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
HERITAGE GLOBAL INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2017 | FY2018 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Federal Statutory Rate | 35.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | 7.10% | 7.30% | 9.20% |
| Foreign Rate Differential | — | — | — | — | — |
| Other Adjustments | — | — | — | -0.20% | 1.00% |
| Nondeductible Expenses | — | — | 10.10% | 41.80% | — |
| Valuation Allowance Change | — | — | -15.80% | 13.90% | -60.10% |
| Effective Tax Rate | — | — | — | 41.90% | 38.60% |
Cash vs Accrual
| Item | FY2017 | FY2018 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$420.0K | $270.0K | $1.5M | $3.8M | $2.3M |
| Income Taxes Paid (Cash) | — | — | — | — | $700.0K |
HERITAGE GLOBAL INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
HGP
Purchase-Price Allocation
Goodwill
$2.0M
Alt
Purchase-Price Allocation
Goodwill
$1.9M